Cybin Inc., a clinical-stage biopharmaceutical company, announced on May 6, 2024, significant progress in its development pipeline, including a recent U.S. $150 million funding round and the FDA Breakthrough Therapy Designation for its lead program CYB003. CYB003, a deuterated psilocybin analog, is being developed for the adjunctive treatment of Major Depressive Disorder (MDD) and has shown promising Phase 2 results. The company plans to initiate a Phase 3 study for CYB003 in MDD by mid-2024. Additionally, Cybin is advancing CYB004, a deuterated N,N-dimethyltryptamine (DMT) program for Generalized Anxiety Disorder (GAD), with Phase 2 topline efficacy and safety results expected in Q4 2024. Cybin's intellectual property portfolio includes over 50 granted patents and over 170 pending applications, supporting its clinical programs and drug discovery platforms. The company also highlighted its EMBARK training program, designed to prepare facilitators for clinical trials involving psychedelic therapeutics. Cybin's mission is to revolutionize mental healthcare with innovative psychedelic-based treatments.

Cybin Inc., a clinical-stage biopharmaceutical company, announced on May 6, 2024, significant progress in its development pipeline, including a recent U.S. $150 million funding round and the FDA Breakthrough Therapy Designation for its lead program CYB003. CYB003, a deuterated psilocybin analog, is being developed for the adjunctive treatment of Major Depressive Disorder (MDD) and has shown promising Phase 2 results. The company plans to initiate a Phase 3 study for CYB003 in MDD by mid-2024. Additionally, Cybin is advancing CYB004, a deuterated N,N-dimethyltryptamine (DMT) program for Generalized Anxiety Disorder (GAD), with Phase 2 topline efficacy and safety results expected in Q4 2024. Cybin's intellectual property portfolio includes over 50 granted patents and over 170 pending applications, supporting its clinical programs and drug discovery platforms. The company also highlighted its EMBARK training program, designed to prepare facilitators for clinical trials involving psychedelic therapeutics. Cybin's mission is to revolutionize mental healthcare with innovative psychedelic-based treatments.